Viral infections Archives | Report Store

Disease Analysis: COVID-19 Prevention

COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of 27 November 2020, there have been 60,704,174 confirmed cases of COVID-19, and 1,416,292 confirmed deaths globally.

December 1, 2020

Find out more

Disease Analysis: COVID-19 Treatment

COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of 24 November 2020, there have been 58,712,326 confirmed cases of COVID-19, and 1,388,528 confirmed deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus. SARS-CoV-2 is believed to have originated from a horseshoe bat coronavirus, which either spread to humans directly or jumped via an intermediate host (possibly a pangolin), which may have facilitated transmission to humans

November 25, 2020

Find out more

Dengue Vaccines

Dengue fever is an emerging flaviviral infection transmitted mainly by Aedes aegypti and Aedes albopictus mosquitoes.

November 13, 2020

Find out more

Market Spotlight: Zika virus

$1,318.00

This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, probability of success, epidemiology, and licensing and acquisition deals.

November 12, 2020

Find out more

Market Spotlight: Hepatitis B

$1,318.00

This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success,patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

November 5, 2020

Find out more

Market Spotlight: Norovirus

$1,318.00

This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, recent events, and an epidemiological overview.

October 22, 2020

Find out more

Disease Analysis: Hepatitis C

Hepatitis C (HCV) product revenues will decline significantly during the 2020–29 forecast period, with sales in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) falling from $3.2bn to $1.3bn, at a compound annual growth rate of -9.4%. With no new pipeline agents expected to gain approval, and fierce pricing competition between established players ruling out the annual price increases typically observed in the lucrative US market, the erosion in market value will be primarily driven by a stepwise decline in patient numbers as the influx of newly diagnosed patients fails to offset the high number of patients exiting the treatment algorithm due to cure.

October 15, 2020

Find out more

Hepatitis B disease forecast and market analysis to 2035

Hepatitis B is a viral infection caused by the hepatitis B virus (HBV) that attacks the liver and can cause both acute and chronic disease. HBV is transmitted perinatally from mother to child and through contact with infected blood or other bodily fluids. Despite a safe and effective vaccine being available, HBV continues to represent a major health problem and can lead to acute liver failure, acute hepatitis, chronic hepatitis, liver cirrhosis, liver cancer, liver transplantation, and death.

October 25, 2018

Find out more

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interviews

$599.00

Datamonitor Healthcare interviewed two infectious disease experts, one based in the US and one in France, to gauge their views on the seasonal influenza vaccines market, its outlook over the next five years and any key events that are likely to take place, including the impact of novel quadrivalent inactivated influenza vaccines and other incremental advances

April 18, 2017

Find out more